Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11064 | 0.91 | MAPK1 (0.48) | MAPK1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL10401 | 0.91 | MAPK1 (0.48) | MAPK1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL5765 | 0.86 | KDM4E (0.51) | MAPK1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL5949120 | 0.84 | POLB (0.38) | MAPK1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL28108062 | 0.83 | KMT2A (0.40) | MEN1KMT2AMAPTL3MBTL1LMNA | |
| SCHEMBL5949812 | 0.82 | POLB (0.41) | KDM4EMEN1KMT2AMAPTATM | |
| SCHEMBL15166991 | 0.80 | POLB (0.40) | KDM4EMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL16628708 | 0.80 | KCNA3 (0.35) | MAPK1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL743660 | 0.79 | MAPK1 (0.53) | MAPK1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL17162705 | 0.79 | POLB (0.39) | MEN1KMT2AATMLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688881-B1 | NEW AZASPIRODECANONE COMPOUNDS AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2016-02-10 | — | — | EP | disclosed |
| EP-2688881-B1 | NEW AZASPIRODECANONE COMPOUNDS AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2016-02-10 | — | — | EP | disclosed |
| EP-2488493-B1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-8809384-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809384-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809384-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8722721-B2 | SEC-hydroxycyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722721-B2 | SEC-hydroxycyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722721-B2 | SEC-hydroxycyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8703807-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2012123432-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES AS HSL INHIBITORS FOR THE TREATMENT DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238594-A1 | AZASPIRODECANONE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-09-20 | — | — | US | disclosed |
| WO-2012123432-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES AS HSL INHIBITORS FOR THE TREATMENT DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012123468-A1 | NEW AZASPIRODECANONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238613-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| EP-2488493-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| WO-2011045292-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238613-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES | SEC61B, SEC61A1, SEC22B | MAPK1 2574/4885KDM4E 3279/4885MEN1 887/4885 |
| US-20120238594-A1 | AZASPIRODECANONE COMPOUNDS | CYP51A1, HSD17B7, NR5A1 | MAPK1 3731/4885KDM4E 277/4885MEN1 320/4885 |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LPL, MGLL, LIPE | MAPK1 2336/4885KDM4E 3143/4885MEN1 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.